Nippon Chemiphar Co., Ltd. (TYO:4539)
1,611.00
-19.00 (-1.17%)
May 29, 2026, 10:53 AM JST
Nippon Chemiphar Revenue
In the fiscal year ending March 31, 2026, Nippon Chemiphar had annual revenue of 33.09B JPY with 1.60% growth. Nippon Chemiphar had revenue of 8.83B in the quarter ending March 31, 2026, with 6.90% growth.
Revenue
33.09B
Revenue Growth
+1.60%
P/S Ratio
0.18
Revenue / Employee
38.70M
Employees
855
Market Cap
5.81B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 33.09B | 520.00M | 1.60% |
| Mar 31, 2025 | 32.57B | 1.82B | 5.93% |
| Mar 31, 2024 | 30.75B | -811.00M | -2.57% |
| Mar 31, 2023 | 31.56B | -947.00M | -2.91% |
| Mar 31, 2022 | 32.51B | 965.00M | 3.06% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pharma Foods International | 67.84B |
| Fuso Pharmaceutical Industries,Ltd. | 62.17B |
| Morishita Jintan | 12.69B |
| Wakamoto Pharmaceutical | 9.43B |
| Taiko Pharmaceutical | 6.16B |
| WDB coco | 4.82B |
| SymBio Pharmaceuticals | 1.28B |
| Solasia Pharma K.K. | 410.00M |